

Michael W Ronellenfitsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3066960/publications.pdf>

Version: 2024-02-01

57
papers

1,551
citations

331670

21
h-index

330143

37
g-index

59
all docs

59
docs citations

59
times ranked

5122
citing authors

#	ARTICLE	IF	CITATIONS
1	The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. <i>Neuro-Oncology</i> , 2022, 24, 213-225.	1.2	36
2	Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial. <i>European Journal of Nutrition</i> , 2022, 61, 477-487.	3.9	16
3	Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy. <i>European Journal of Neurology</i> , 2022, 29, 543-554.	3.3	1
4	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. <i>Neurology</i> , 2022, 98, .	1.1	2
5	Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients. <i>Current Oncology</i> , 2022, 29, 2225-2239.	2.2	2
6	Linking epigenetic signature and metabolic phenotype in <i>IDH</i> mutant and <i>IDH</i> wildtype diffuse glioma. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 379-393.	3.2	4
7	Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients. <i>Journal of Molecular Histology</i> , 2021, 52, 233-243.	2.2	8
8	A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2373-2383.	2.5	2
9	Single-shot bevacizumab for cerebral radiation injury. <i>BMC Neurology</i> , 2021, 21, 77.	1.8	8
10	Meningioma Surgery in Patients ≥70 Years of Age: Clinical Outcome and Validation of the SKALE Score. <i>Journal of Clinical Medicine</i> , 2021, 10, 1820.	2.4	5
11	Clinical Outcome and Risk Factors of Red Blood Cell Transfusion in Patients Undergoing Elective Primary Meningioma Resection. <i>Cancers</i> , 2021, 13, 3601.	3.7	8
12	Activating transcription factor 4 mediates adaptation of human glioblastoma cells to hypoxia and temozolomide. <i>Scientific Reports</i> , 2021, 11, 14161.	3.3	11
13	Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization. <i>Frontiers in Immunology</i> , 2021, 12, 798811.	4.8	9
14	Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death. <i>Cancers</i> , 2020, 12, 2144.	3.7	6
15	Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3050.	3.7	1
16	Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition. <i>OncImmunology</i> , 2020, 9, 1851517.	4.6	12
17	Serine-dependent redox homeostasis regulates glioblastoma cell survival. <i>British Journal of Cancer</i> , 2020, 122, 1391-1398.	6.4	41
18	ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 987-995.	0.8	46

#	ARTICLE	IF	CITATIONS
19	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 2488-2495.	8.2	23
20	AMPK activation protects astrocytes from hypoxia-induced cell death. <i>International Journal of Molecular Medicine</i> , 2020, 45, 1385-1396.	4.0	9
21	Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1608.	2.4	2
22	Treatment of refractory and superrefractory status epilepticus with topiramate: A cohort study of 106 patients and a review of the literature. <i>Epilepsia</i> , 2019, 60, 2448-2458.	5.1	30
23	Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4474.	4.1	19
24	Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. <i>Acta Neuropathologica</i> , 2019, 138, 331-334.	7.7	22
25	The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma. <i>British Journal of Cancer</i> , 2019, 120, 481-487.	6.4	45
26	Multicenter cohort study on the use of topiramate in the treatment of refractory and super-refractory status epilepticus. <i>Epilepsy and Behavior</i> , 2019, 101, 106800.	1.7	0
27	Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 2031.	2.4	23
28	Disruption of peroxisome proliferator-activated receptor β coactivator (PGC)-1 α reverts key features of the neoplastic phenotype of glioma cells. <i>Journal of Biological Chemistry</i> , 2019, 294, 3037-3050.	3.4	18
29	EGFR and mTOR as therapeutic targets in glioblastoma. <i>Oncotarget</i> , 2019, 10, 4721-4723.	1.8	7
30	Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 975-985.	1.2	11
31	<i>CASP9</i> germline mutation in a family with multiple brain tumors. <i>Brain Pathology</i> , 2018, 28, 94-102.	4.1	11
32	Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1504.	4.1	25
33	Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 81.	5.2	22
34	Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2462.	4.1	21
35	Personalized translational epilepsy research – Novel approaches and future perspectives. <i>Epilepsy and Behavior</i> , 2017, 76, 7-12.	1.7	14
36	Personalized translational epilepsy research – Novel approaches and future perspectives. <i>Epilepsy and Behavior</i> , 2017, 76, 13-18.	1.7	26

#	ARTICLE	IF	CITATIONS
37	Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. <i>Oncology Letters</i> , 2017, 14, 1141-1146.	1.8	58
38	Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death. <i>Brain</i> , 2017, 140, 2623-2638.	7.6	30
39	Effects of soluble CPE on glioma cell migration are associated with mTOR activation and enhanced glucose flux. <i>Oncotarget</i> , 2017, 8, 67567-67591.	1.8	11
40	Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. <i>Oncology Reports</i> , 2017, 38, 3291-3296.	2.6	46
41	Activation of AMP-activated kinase modulates sensitivity of glioma cells against epidermal growth factor receptor inhibition. <i>International Journal of Oncology</i> , 2016, 49, 173-180.	3.3	8
42	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O ⁶ -Methylguanine- ⁸ -DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1611-1619.	1.6	151
43	Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study. <i>PLoS ONE</i> , 2016, 11, e0168113.	2.5	19
44	Diagnostic and clinical relevance of the autophago-lysosomal network in human gliomas. <i>Oncotarget</i> , 2016, 7, 20016-20032.	1.8	32
45	Immunohistochemical Assessment of Phosphorylated mTORC1-Pathway Proteins in Human Brain Tumors. <i>PLoS ONE</i> , 2015, 10, e0127123.	2.5	15
46	ANGI-02PERIOPERATIVE CEREBRAL ISCHEMIA PROMOTE INFILTRATIVE RECURRENCE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v41.2-v41.	1.2	0
47	Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma. <i>Oncotarget</i> , 2015, 6, 14537-14544.	1.8	27
48	Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. <i>Oncotarget</i> , 2015, 6, 40836-40849.	1.8	106
49	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 409-414.	7.1	152
50	Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. <i>Neurology</i> , 2014, 83, 227-234.	1.1	28
51	Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid. <i>PLoS ONE</i> , 2014, 9, e94921.	2.5	13
52	Tumor necrosis factor receptor superfamily member 9 is upregulated in the endothelium and tumor cells in melanoma brain metastasis. <i>Neuroimmunology and Neuroinflammation</i> , 2014, 1, 135.	1.4	0
53	Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. <i>Oncogene</i> , 2012, 31, 3764-3776.	5.9	52
54	Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. <i>Targeted Oncology</i> , 2010, 5, 183-191.	3.6	23

#	ARTICLE	IF	CITATIONS
55	The Pan-Bcl-2 Inhibitor (̂~)-Gossypol Triggers Autophagic Cell Death in Malignant Glioma. <i>Molecular Cancer Research</i> , 2010, 8, 1002-1016.	3.4	169
56	Bevacizumab-Induced Diffusion Restriction in Patients With Glioma: Tumor Progression or Surrogate Marker of Hypoxia?. <i>Journal of Clinical Oncology</i> , 2010, 28, e477-e477.	1.6	21
57	Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. <i>Brain</i> , 2009, 132, 1509-1522.	7.6	42